Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585180 | 0.94 | GPR6 (0.42) | ROCK2CACNA1HALDH1A1KDM4EGPR6 | |
| SCHEMBL3577858 | 0.91 | ROCK2 (0.48) | ROCK2CACNA1HP2RX7FEN1P2RX3 | |
| SCHEMBL3585603 | 0.88 | KDM4E (0.40) | ROCK2ALDH1A1KDM4EGPR6P2RX7 | |
| SCHEMBL3582189 | 0.88 | ROCK2 (0.47) | ROCK2CACNA1HP2RX7FEN1P2RX3 | |
| SCHEMBL3577356 | 0.88 | ROCK2 (0.42) | ROCK2P2RX7FEN1P2RX3 | |
| SCHEMBL3588811 | 0.88 | ROCK2 (0.42) | ROCK2P2RX7P2RX3 | |
| SCHEMBL3582434 | 0.87 | ROCK2 (0.40) | ROCK2CACNA1HP2RX7FEN1P2RX3 | |
| SCHEMBL3582483 | 0.86 | ROCK2 (0.41) | ROCK2CACNA1HP2RX7FEN1P2RX3 | |
| SCHEMBL3577845 | 0.86 | P2RX7 (0.44) | ROCK2P2RX7P2RX3 | |
| SCHEMBL3583383 | 0.86 | ROCK2 (0.40) | ROCK2CACNA1HP2RX7P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104670-B3 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-09-21 | — | — | EP | claimed |
| EP-2104670-B1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-02-17 | — | — | EP | claimed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | claimed |
| EP-2662366-A1 | Novel triazinedione derivatives as GABA-B receptor modulators | ADDEX Pharma S.A. (CH) | 2013-11-13 | — | — | EP | claimed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | claimed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | claimed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2662366-A1 | Novel triazinedione derivatives as GABA-B receptor modulators | ADDEX Pharma S.A. (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-2104670-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | Addex Pharma SA (CH) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008056257-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMA S.A (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ROCK2 2382/4885CACNA1H 430/4885ALDH1A1 3515/4885 |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ROCK2 2382/4885CACNA1H 430/4885ALDH1A1 3515/4885 |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ROCK2 2382/4885CACNA1H 430/4885ALDH1A1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.